{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:50:15Z","timestamp":1793155815486,"version":"4.5.0"},"reference-count":109,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Interleukins (ILs) are vital in regulating the immune system, enabling to combat fungal diseases like candidiasis effectively. Their inhibition may cause enhanced susceptibility to infection. IL inhibitors have been employed to control autoimmune diseases and inhibitors of IL-17 and IL-23, for example, have been associated with an elevated risk of <jats:italic>Candida<\/jats:italic> infection. Thus, applying IL inhibitors might impact an individual\u2019s susceptibility to <jats:italic>Candida<\/jats:italic> infections. Variations in the severity of <jats:italic>Candida<\/jats:italic> infections have been observed between individuals with different IL inhibitors, necessitating careful consideration of their specific risk profiles. IL-1 inhibitors (anakinra, canakinumab, and rilonacept), IL-2 inhibitors (daclizumab, and basiliximab), and IL-4 inhibitors (dupilumab) have rarely been associated with <jats:italic>Candida<\/jats:italic> infection. In contrast, tocilizumab, an inhibitor of IL-6, has demonstrated an elevated risk in the context of coronavirus disease 2019 (COVID-19) treatment, as evidenced by a 6.9% prevalence of candidemia among patients using the drug. Furthermore, the incidence of <jats:italic>Candida<\/jats:italic> infections appeared to be higher in patients exposed to IL-17 inhibitors than in those exposed to IL-23 inhibitors. Therefore, healthcare practitioners must maintain awareness of the risk of candidiasis associated with using of IL inhibitors before prescribing them. Future prospective studies need to exhaustively investigate candidiasis and its associated risk factors in patients receiving IL inhibitors. Implementing enduring surveillance methods is crucial to ensure IL inhibitors safe and efficient utilization of in clinical settings.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1372693","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T05:09:05Z","timestamp":1711602545000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Interleukin inhibitors and the associated risk of candidiasis"],"prefix":"10.3389","volume":"15","author":[{"given":"Sabir","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazrat","family":"Bilal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Nadeem","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-jing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongrong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuebin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.2174\/1871526515666150320162036","article-title":"Candidiasis: a fungal infection\u2013current challenges and progress in prevention and treatment","volume":"15","author":"Hani","year":"2015","journal-title":"Infect Disord Drug Targets"},{"key":"B2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/TCRM","article-title":"Epidemiology and risk factors for invasive candidiasis","volume":"10","author":"Yapar","year":"2014","journal-title":"Ther Clin Risk Manag"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2022.2123325","article-title":"Distribution and antifungal susceptibility pattern of Candida species from mainland China: A systematic analysis","volume":"13","author":"Bilal","year":"2022","journal-title":"Virulence"},{"key":"B4","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2741\/3263","article-title":"Role of Toll-like receptors in systemic Candida albicans infections","volume":"21","author":"Luisa Gil","year":"2016","journal-title":"Front bioscience (Landmark edition)"},{"key":"B5","first-page":"13","article-title":"Interleukins (ILs), a fascinating family of cytokines. Part I: ILs from IL-1 to IL-19","volume":"107","author":"Fietta","year":"2014","journal-title":"Theor Biol Forum"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2011.05154.x","article-title":"The roles of cells and cytokines in the pathogenesis of psoriasis","volume":"51","author":"Coimbra","year":"2012","journal-title":"Int J Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3895","article-title":"IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases","volume":"21","author":"Teng","year":"2015","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.it.2005.10.003","article-title":"Understanding the IL-23-IL-17 immune pathway","volume":"27","author":"McKenzie","year":"2006","journal-title":"Trends Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/832454","article-title":"Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27","author":"Xu","year":"2010","journal-title":"Clin Dev Immunol 2010"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2015.1004977","article-title":"Adaptive immune responses to Candida albicans infection","volume":"6","author":"Richardson","year":"2015","journal-title":"Virulence"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2010.22","article-title":"IL-22 defines a novel immune pathway of antifungal resistance","volume":"3","author":"De Luca","year":"2010","journal-title":"Mucosal Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001153","article-title":"IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans","volume":"185","author":"Kagami","year":"2010","journal-title":"J Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1084\/jem.20091669","article-title":"Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines","volume":"207","author":"Kisand","year":"2010","journal-title":"J Exp Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.12788\/cutis","article-title":"Risk for deep fungal infections during IL-17 and IL-23 inhibitor therapy for psoriasis","volume":"106","author":"Lee","year":"2020","journal-title":"Cutis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2020.02.001","article-title":"Risk of serious infection associated with agents that target T-cell activation and interleukin-17 and interleukin-23 cytokines","volume":"34","author":"Shoor","year":"2020","journal-title":"Infect Dis Clin North Am"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2442603","DOI":"10.1155\/2022\/2442603","article-title":"Risk of candida infection and serious infections in patients with moderate-to-severe psoriasis receiving biologics: A systematic review and meta-analysis of randomized controlled trials","volume":"2022","author":"Feng","year":"2022","journal-title":"Int J Clin Pract"},{"key":"B17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/cpt.893","article-title":"Anti-IL-23 and anti-IL-17 biologic agents for the treatment of immune-mediated inflammatory conditions","volume":"103","author":"Frieder","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2174\/1566524033479366","article-title":"Regulation of dendritic cell function through toll-like receptors","volume":"3","author":"Kaisho","year":"2003","journal-title":"Curr Mol Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2013.07.006","article-title":"Dendritic cells and other innate determinants of T helper cell polarisation","volume":"34","author":"Walsh","year":"2013","journal-title":"Trends Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.20.100301.064828","article-title":"Antigen presentation and T cell stimulation by dendritic cells","volume":"20","author":"Guermonprez","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"110550","DOI":"10.1016\/j.biopha.2020.110550","article-title":"Immune defence to invasive fungal infections: A comprehensive review","volume":"130","author":"Pathakumari","year":"2020","journal-title":"Biomedicine pharmacotherapy = Biomedecine pharmacotherapie"},{"key":"B22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/ijms22010057","article-title":"and testicular immunity: A new insight into immune regulation in testes","volume":"22","author":"Gong","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11046-018-0301-6","article-title":"Different host immunological response to C. albicans by human oral and vaginal epithelial cells","volume":"184","author":"Gao","year":"2019","journal-title":"Mycopathologia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05397.x","article-title":"The immune response to fungal infections","volume":"129","author":"Shoham","year":"2005","journal-title":"Br J haematology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1084\/jem.20081463","article-title":"Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis","volume":"206","author":"Conti","year":"2009","journal-title":"J Exp Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"18026","DOI":"10.1038\/nrdp.2018.26","article-title":"Invasive candidiasis","volume":"4","author":"Pappas","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.139","article-title":"Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22","volume":"128","author":"Eyerich","year":"2008","journal-title":"J Invest Dermatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2366","article-title":"IL-12 family cytokines: immunological playmakers","volume":"13","author":"Vignali","year":"2012","journal-title":"Nat Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2015.07.005","article-title":"Insights into IL-23 biology: From structure to function","volume":"26","author":"Floss","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/35038103","article-title":"Development of Th1-type immune responses requires the type I cytokine receptor TCCR","volume":"407","author":"Chen","year":"2000","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2007.10.007","article-title":"Th17 cells: effector T cells with inflammatory properties","volume":"19","author":"Korn","year":"2007","journal-title":"Semin Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008115","article-title":"IL-23 supports host defense against systemic Candida albicans infection by ensuring myeloid cell survival","volume":"15","author":"Nur","year":"2019","journal-title":"PLoS Pathog"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.26250","article-title":"The role of innate lymphoid cells in health and disease","volume":"233","author":"Mohammadi","year":"2018","journal-title":"J Cell Physiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"102382","DOI":"10.1016\/j.jaut.2019.102382","article-title":"Innate immunity as the trigger of systemic autoimmune diseases","volume":"110","author":"Saferding","year":"2020","journal-title":"J Autoimmun"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxq442","article-title":"The Candida Th17 response is dependent on mannan- and beta-glucan-induced prostaglandin E2","volume":"22","author":"Smeekens","year":"2010","journal-title":". Int Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12183","article-title":"Directing traffic: IL-17 and IL-22 coordinate pulmonary immune defense","volume":"260","author":"McAleer","year":"2014","journal-title":"Immunol Rev"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1086\/422329","article-title":"Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice","volume":"190","author":"Huang","year":"2004","journal-title":"J Infect Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12027","article-title":"IL-22, not simply a Th17 cytokine","volume":"252","author":"Rutz","year":"2013","journal-title":"Immunol Rev"},{"key":"B40","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12967-017-1141-8","article-title":"Immune modulation of some autoimmune diseases: the critical role of macrophages and neutrophils in the innate and adaptive immunity","volume":"15","author":"Navegantes","year":"2017","journal-title":"J Transl Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4161\/viru.1.5.12983","article-title":"Antimicrobial peptides: the ancient arm of the human immune system","volume":"1","author":"Wiesner","year":"2010","journal-title":"Virulence"},{"key":"B42","doi-asserted-by":"publisher","first-page":"346307","DOI":"10.1155\/2011\/346307","article-title":"Mucosal immunity and Candida albicans infection","volume":"2011","author":"Moyes","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.03.026","article-title":"Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)","volume":"77","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discovery"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2013.10.008","article-title":"Treating inflammation by blocking interleukin-1 in humans","volume":"25","author":"Dinarello","year":"2013","journal-title":"Semin Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.9.972","article-title":"Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage","volume":"41","author":"Abramson","year":"2002","journal-title":"Rheumatol (Oxford England)"},{"key":"B47","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clim.2018.10.016","article-title":"Targeting cytokines to treat autoinflammatory diseases","volume":"206","author":"Hausmann","year":"2019","journal-title":"Clin Immunol (Orlando Fla.)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.048371","article-title":"Safety of extended treatment with anakinra in patients with rheumatoid arthritis","volume":"65","author":"Fleischmann","year":"2006","journal-title":"Ann rheumatic Dis"},{"key":"B49","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.msard.2016.05.010","article-title":"Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies","volume":"9","author":"Giovannoni","year":"2016","journal-title":"Multiple sclerosis related Disord"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/art.39093","article-title":"Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: Results of a phase III study","volume":"67","author":"Genovese","year":"2015","journal-title":"Arthritis Rheumatol (Hoboken N.J.)"},{"key":"B51","doi-asserted-by":"publisher","first-page":"102564","DOI":"10.1016\/j.autrev.2020.102564","article-title":"Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia","volume":"19","author":"Antinori","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab562","article-title":"The landscape of candidemia during the coronavirus disease 2019 (COVID-19) pandemic","volume":"74","author":"Seagle","year":"2022","journal-title":"Clin Infect Dis an Off Publ Infect Dis Soc America"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"New Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19132","article-title":"Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1)","volume":"183","author":"Papp","year":"2020","journal-title":"Br J Dermatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.095","article-title":"Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial","volume":"82","author":"Puig","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2013results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"New Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet (London England)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202371","article-title":"Effect of IL-17A blockade with secukinumab in autoimmune diseases","author":"Patel","year":"2013","journal-title":"Ann rheumatic Dis 72 Suppl 2"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet (London England)"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMc1610828","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"New Engl J Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.11.022","article-title":"Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial","volume":"85","author":"Blauvelt","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2113092","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Griffith","year":"2021","journal-title":"New Engl J Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet (London England)"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"New Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad115","article-title":"Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: Pooled analyses across seven clinical trials with greater than 8600 patient-years of exposure","volume":"189","author":"Lebwohl","year":"2023","journal-title":"Br J Dermatol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20595","article-title":"Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up","volume":"185","author":"Papp","year":"2021","journal-title":"Br J Dermatol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219014","article-title":"Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study","volume":"80","author":"Mease","year":"2021","journal-title":"Ann rheumatic Dis"},{"key":"B69","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s13311-012-0147-4","article-title":"Daclizumab therapy for multiple sclerosis","volume":"10","author":"Bielekova","year":"2013","journal-title":"Neurother J Am Soc Exp Neurother"},{"key":"B70","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.expneurol.2014.04.015","article-title":"Daclizumab (anti-CD25) in multiple sclerosis","volume":"262","author":"Pfender","year":"2014","journal-title":"Exp Neurol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/qjmed\/hcg014","article-title":"Clinical advances in therapies targeting the interleukin-2 receptor","volume":"96","author":"Church","year":"2003","journal-title":"QJM monthly J Assoc Physicians"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9091096","article-title":"The role of dupilumab in severe asthma","volume":"9","author":"Ricciardolo","year":"2021","journal-title":"Biomedicines"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2011.03.023","article-title":"Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases","volume":"585","author":"Tanaka","year":"2011","journal-title":"FEBS Lett"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1159\/000229021","article-title":"Tocilizumab inhibits interleukin-6-mediated matrix metalloproteinase-2 and -9 secretions from human amnion cells in preterm premature rupture of membranes","volume":"68","author":"Mano","year":"2009","journal-title":"Gynecologic obstetric Invest"},{"key":"B75","doi-asserted-by":"publisher","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0929-z","article-title":"Sarilumab: A review in moderate to severe rheumatoid arthritis","volume":"78","author":"Lamb","year":"2018","journal-title":"Drugs"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.2377","article-title":"Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease","volume":"28","author":"van Rhee","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000841","article-title":"Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology","volume":"7","author":"Fujihara","year":"2020","journal-title":"Neurology(R) neuroimmunology Neuroinflamm"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1080\/15424065.2012.735134","article-title":"Drugs and lactation database (LactMed)","author":"Bethesda","year":"2006","journal-title":"Natl Library Med (US): Bethesda MD USA"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22136740","article-title":"From messengers to receptors in psoriasis: The role of IL-17RA in disease and treatment","volume":"22","author":"Vidal","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized igG1 antibody that neutralizes both IL-17A and IL-17F","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"New Engl J Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19020530","article-title":"Role of the IL-23\/IL-17 axis in psoriasis and psoriatic arthritis: The clinical importance of its divergence in skin and joints","volume":"19","author":"Boutet","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B84","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1002\/msc.1694","article-title":"The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis","author":"Fragoulis","year":"2022","journal-title":"Musculoskeletal Care"},{"key":"B85","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jmb.2010.07.046","article-title":"Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab","volume":"402","author":"Luo","year":"2010","journal-title":"J Mol Biol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1903","article-title":"Therapeutic targeting of the IL-12\/23 pathways: generation and characterization of ustekinumab","volume":"29","author":"Benson","year":"2011","journal-title":"Nat Biotechnol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1356498","article-title":"Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis","volume":"13","author":"Jeon","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"B88","article-title":"Ustekinumab","author":"Colquhoun","year":"2021"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000147","article-title":"Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis","volume":"27","author":"Mease","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"B90","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR)","volume":"14","author":"Papp","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1292137","article-title":"The role of IL 23 in the treatment of psoriasis","volume":"13","author":"Puig","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"B92","first-page":"8","article-title":"A review of guselkumab, an IL-23 inhibitor, for moderate-to-severe plaque psoriasis","volume":"22","author":"Nawas","year":"2017","journal-title":"Skin Ther Lett"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00578-0","article-title":"Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: A comprehensive review","volume":"22","author":"Yang","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"New Engl J Med"},{"key":"B96","doi-asserted-by":"publisher","first-page":"ofac343","DOI":"10.1093\/ofid\/ofac343","article-title":"Safety and efficacy of dupilumab for the treatment of hospitalized patients with moderate to severe coronavirus disease 2019: A phase 2a trial","volume":"9","author":"Sasson","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2020.05.021","article-title":"Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study","volume":"76","author":"Campochiaro","year":"2020","journal-title":"Eur J Internal Med"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3390\/life13081752","article-title":"Tocilizumab is associated with increased risk of fungal infections among critically ill patients with COVID-19 and acute renal failure: An observational cohort study","volume":"13","author":"Burger","year":"2023","journal-title":"Life (Basel Switzerland)"},{"key":"B99","doi-asserted-by":"publisher","first-page":"100266","DOI":"10.1016\/j.lanepe.2021.100266","article-title":"Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources","volume":"13","author":"Davidson","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19328","article-title":"Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors - A population-based study","volume":"37","author":"Kridin","year":"2023","journal-title":"J Eur Acad Dermatol Venereology JEADV"},{"key":"B101","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40257-022-00722-y","article-title":"Drug survival of interleukin (IL)\u221217 and IL\u221223 inhibitors for the treatment of psoriasis: A retrospective multi\u2212country, multicentric cohort study","volume":"23","author":"Torres","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21501203.2023.2265664","article-title":"Risk of candidiasis associated with interleukin-17 inhibitors: implications and management","author":"Bilal","year":"2023","journal-title":"Mycology"},{"key":"B103","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/d41586-022-01245-6","article-title":"15 million people have died in the pandemic, WHO says","volume":"605","author":"Adam","year":"2022","journal-title":"Nature"},{"key":"B104","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s13054-020-03020-3","article-title":"Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients","volume":"24","author":"Convertino","year":"2020","journal-title":"Crit Care (London England)"},{"key":"B105","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/1759720X221116405","article-title":"Successful treatment of severe COVID-19 pneumonia, a case series with simultaneous interleukin-1 and interleukin-6 blockade with 1-month follow-up","volume":"4","author":"Haibel","year":"2022","journal-title":"Ther Adv musculoskeletal Dis"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2006.06.004","article-title":"Is IL-1 a good therapeutic target in the treatment of arthritis","volume":"20","author":"Burger","year":"2006","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"106296","DOI":"10.1016\/j.intimp.2020.106296","article-title":"Interleukin-2 as immunotherapeutic in the autoimmune diseases","volume":"81","author":"Orozco Valencia","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.2174\/13894501113146660224","article-title":"Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target","volume":"14","author":"Allocca","year":"2013","journal-title":"Curr Drug Targets"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00826-w","article-title":"Immune responses to human fungal pathogens and therapeutic prospects","volume":"23","author":"Lionakis","year":"2023","journal-title":"Nat Rev Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1372693\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T05:09:30Z","timestamp":1711602570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1372693\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,28]]},"references-count":109,"alternative-id":["10.3389\/fimmu.2024.1372693"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1372693","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,28]]},"article-number":"1372693"}}